Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | PTAFR | P25105 | 8/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21176346 | 0.74 | ALDH1A1 (0.56) | ALDH1A1HPGDPOLBSMN1; SMN2GAA | |
| SCHEMBL19975516 | 0.72 | KMT2A (0.41) | ALDH1A1HPGDPOLBSMN1; SMN2GAA | |
| SCHEMBL21176343 | 0.72 | ALDH1A1 (0.46) | ALDH1A1HPGDPOLBSMN1; SMN2GAA | |
| SCHEMBL28876091 | 0.71 | ESR1 (0.41) | ALDH1A1HPGDPOLBSMN1; SMN2PKM | |
| SCHEMBL28316331 | 0.69 | HPGD (0.40) | HPGDPOLBSMN1; SMN2LMNAHTT | |
| SCHEMBL22445205 | 0.69 | ALDH1A1 (0.47) | ALDH1A1GAAPKMLMNA | |
| SCHEMBL10666702 | 0.66 | PTAFR (0.49) | ALDH1A1PTAFRPOLBSMN1; SMN2 | |
| SCHEMBL19974842 | 0.65 | KMT2A (0.43) | ALDH1A1HPGDPOLBSMN1; SMN2GAA | |
| SCHEMBL25183106 | 0.64 | LMNA (0.48) | SLC1A5LMNA | |
| SCHEMBL10618105 | 0.64 | LMNA (0.43) | PTAFRPKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | ALDH1A1 2271/4885PTAFR 1096/4885HPGD 1205/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | ALDH1A1 2271/4885PTAFR 1096/4885HPGD 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.